Welcome to our dedicated page for IceCure Medical Ltd. SEC filings (Ticker: ICCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IceCure Medical Ltd. filings document the company’s status as a foreign private issuer and its disclosures around ProSense cryoablation technology, clinical and regulatory updates, commercial activity, governance and capital structure. Form 6-K reports furnish press releases on financial and operating results, FDA-related matters, medical-conference updates and clinical data for ProSense in tumor-destruction applications.
The filing record also includes proxy materials for shareholder voting, registration-statement references on Forms F-3 and S-8, ordinary-share voting information, executive and board changes, employment and indemnification arrangements, and litigation disclosure related to a prior private placement. These filings frame ICCM’s formal reporting around its medical-device business and public-company obligations.
IceCure Medical Ltd. held a Special General Meeting of Shareholders on May 11, 2026. The meeting was initially adjourned at 5:00 p.m. Israel time because there was no quorum, but it reconvened at 6:30 p.m., when a quorum was present.
At the adjourned meeting, shareholders voted on and approved the single agenda item described in the company’s proxy statement filed on April 22, 2026. This report is incorporated by reference into IceCure’s existing registration statements on Form F-3 and Form S-8.
IceCure Medical Ltd. has called a Special General Meeting of shareholders for May 11, 2026, to vote on authorizing a potential reverse split of its issued and outstanding ordinary shares at a ratio between 10:1 and 30:1. The Board would have discretion to decide whether to implement the reverse split, the exact ratio within that range, and the effective date. The company states that the goal is to support continued Nasdaq listing, including compliance with the $1.00 minimum bid price requirement, and to potentially make the shares more attractive to a broader investor base. The reverse split would not change the authorized share capital of 2,500,000,000 ordinary shares and is intended to affect all shareholders uniformly.
IceCure Medical expects U.S. revenue from its ProSense® cryoablation systems and cryoprobes to grow more than 30% in the first quarter of 2026 versus the same quarter of 2025, based on preliminary, unaudited estimates. Management links this to adoption following FDA clearance in October 2025 for treating low-risk breast cancer in women aged 70 and above.
The company highlighted strong physician interest at the Society of Breast Imaging 2026 Symposium, where it exhibited ProSense® and supported hands-on training. An award-winning Massachusetts General Hospital cost analysis suggested cryoablation using ProSense® may cut total treatment costs by more than 50% compared to breast-conserving surgery. IceCure plans to report full first-quarter 2026 results on May 14, 2026.
IceCure Medical Ltd. is registering up to 16,000,000 Ordinary Shares for resale by selling shareholders, consisting of up to 8,000,000 shares issuable upon exercise of Series B warrants and up to 8,000,000 shares issuable upon exercise of Series C warrants. No Ordinary Shares are being sold by the company in this registration; the company will receive cash only if the Warrants are exercised. As of March 31, 2026, 81,180,045 Ordinary Shares were issued and outstanding.
The company is offering 8,000,000 Ordinary Shares in a registered direct offering at a combined purchase price of $0.50 per Ordinary Share together with privately placed Series B and Series C warrants.
The offering includes a concurrent private placement of up to 16,000,000 Warrants (8,000,000 Series B Warrants and 8,000,000 Series C Warrants) exercisable at $0.55 per share. Net proceeds are estimated at approximately $3.5 million, intended for working capital and general corporate purposes.
IceCure Medical Ltd. received an amended Schedule 13D from Epoch Partner Investments Limited and its sole director, Mr. Li Haixiang, updating their reporting on ownership and governance. The filing states they beneficially own approximately 45.8% of IceCure’s ordinary shares, based on 73,122,293 shares outstanding as of December 31, 2025.
The amendment primarily reflects that Mr. Li resigned from IceCure’s board of directors on March 17, 2026, and clarifies that Epoch directly holds the shares, while Mr. Li’s beneficial ownership arises from his role as Epoch’s sole director. The reporting persons disclose no share transactions in the past 60 days and no special arrangements regarding the securities.
IceCure Medical Ltd. entered into agreements with healthcare-focused institutional investors for a capital raise combining a registered direct offering and a concurrent private placement. The company agreed to sell 8,000,000 ordinary shares at $0.50 per share in a registered direct offering, for expected gross proceeds of about $4.0 million before fees and expenses.
Concurrently, IceCure will issue unregistered Series B warrants to purchase up to 8,000,000 ordinary shares and Series C warrants to purchase up to 8,000,000 ordinary shares, each with an exercise price of $0.55 per share. The Series B warrants will be exercisable immediately and expire five years after issuance, while the Series C warrants will be exercisable immediately and expire after one year. Net proceeds are currently intended for working capital and general corporate purposes, and closing is expected on or about March 27, 2026, subject to customary conditions.
IceCure Medical Ltd. director Malca Yonatan filed an initial statement of beneficial ownership on Form 3. The provided data shows no reported transactions or derivative positions and no specific share holdings listed, indicating this is a baseline regulatory disclosure of insider status rather than a trading event.